Search results for: Pricing and Reimbursement
Filter search results
OHE Innovation Policy Prize
18 May 2022
…the birth of health economics and has contributed to the development of novel theory and methodology, shaped the major policy and academic debates, and played a role in ultimately improving…
Science, Industry in the State
7 January 1965
…those with an interest in science-based industry, its economics, and its relationship with government; by civil servants, administrators and members of committees; and by all students of this important subject….
Innovation Balance of Payments: the Experience of the Pharmaceutical Industry
1 July 1967
…pattern of international pharmaceutical trade. The next two papers discuss the commercial considerations, such as profitability, pricing, use of brand names and sales promotion, which also affect an industry’s success…
Economics and Innovation the Pharmaceutical Industry
1 July 1969
…Health Economics was concerned to have the pricing policies and other behaviour of the pharmaceutical industry critically explored. Readers who are properly sceptical about the motives and inhibitions of a…
The Publicly Funded Vaccines Market in the UK
1 October 2010
…the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach….
Pharmaceutical Industry and Society: a Study of the Changing Environment and Economics of the International Industry
1 July 1972
…and that is, what is the connection between money spent on research and development and subsequent innovation? My own judgement, after listening to these lectures and reading around the subject,…
Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?
1 October 2009
In this Briefing, five leading European experts in health economics provide a comprehensive international review of changes in health economic evaluation and the reasons for them. The authors express concern…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
…biogeneric, but governments and other payers need to behave differently to encourage this and realise savings. For example, price cuts after patent expiry and/or the use of reference pricing will…
Innovative Competition in Medicine
1 January 1992
…Rt Hon Enoch Powell and Lord Jenkin strayed into the more general field of health care strategies as a whole. Nevertheless the seven papers taken together provide a wide and…